Bertolini Mark T sold $34.9M of OSCR

Bertolini Mark T (Chief Executive Officer) sold 1,206,310 shares of Oscar Health, Inc. (OSCR) at an average of $28.94 ($28.60–$29.79, $34.91M total) across 4 trades over 2026-06-25 to 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bertolini Mark T
Published Jun 29, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OSCR
Neutral
medium confidence
Mentioned
$OSCR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OSCRNeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale size (~1.21M shares; ~$34.9M) and the execution window (June 25–26) under a 10b5-1 plan, which can influence sentiment but is not a fundamental update by itself.

02

Market read

This is a notable insider-sale datapoint for OSCR, but the 10b5-1 structure typically limits interpretive signal.

03

What to watch

Traders should compare with prior insider activity and consider whether the CEO’s remaining stake (8.99M shares) meaningfully changes over time rather than reacting to a single tranche.

Relevance 6/10Novelty 6/10Timing: Form 4 filed June 29 after-hours (transaction dates June 25–26).

Background

The article is an SEC Form 4 insider transaction disclosure for Oscar Health, Inc. (OSCR).

Company-level read

Ticker impact

$OSCRNeutralMedium confidence
Context

Oscar Health CEO Mark T Bertolini sold about $34.9M of OSCR shares via an open-market sale under a 10b5-1 plan (Form 4 filed June 29).

Expected impact

Likely limited, short-lived sentiment impact; follow-through depends on broader fundamentals and other insider activity.

Evidence & confidence

The filing discloses transaction size, pricing range ($28.60–$29.79), and that it was executed under a pre-arranged 10b5-1 plan, which typically reduces signaling risk versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider selling disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale was executed under a pre-arranged 10b5-1 plan, the market may overreact; the disclosure may not reflect new negative information.

Key entities

  • Oscar Health, Inc.

    Subject of the Form 4 insider transaction; CEO sold shares totaling ~$34.9M.

  • Bertolini Mark T

    CEO and director who executed the open-market sales under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$OSCRHighAI 8/10

What Oscar Health (OSCR) Said on Its Q3 Earnings Call

Oscar Health (OSCR) reported Q3 improvements in medical loss ratio (84%) and SG&A expense ratio (14%). The company raised its 2026 outlook, expecting $850M-$950M in earnings from operations and $19B-$19.3B in revenue. Membership grew 27% YoY to 2.7M, but is expected to decline to 2.5M by year-end due to disenrollments. Oscar plans to expand its footprint and products for 2027.

$OSCRMed

Oscar Health Inc (OSCR) Q3 2026 Earnings Call Highlights: Record Profitability, Raised

Oscar Health (OSCR) reported Q3 2026 earnings with record profitability and raised guidance. Membership declined due to CMS reviews, with more disenrollments expected. Q4 SG&A expenses are projected to rise due to seasonal spending. CEO Mark Bertolini and CFO Richard Blackley discussed market share gains, utilization trends, and CMS program integrity initiatives. The company anticipates stable membership and market growth despite competitive pressures and regulatory uncertainties.

$OSCRHighAI 8/10

Oscar Health (OSCR) Q3 2026 Earnings Call Transcript

Oscar Health (OSCR) reported Q3 2026 revenue of $5.1B, up 70% YoY, with membership at 2.7M, up 27% YoY. Net income was $167.3M, reversing a prior-year loss. The company raised full-year guidance for revenue, earnings, and adjusted EBITDA. Management highlighted expansion into new markets, product launches, and operational efficiencies.

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.